- Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injectorPlus, news about Huntington's, Fate Therapeutics and Bausch + Lomb. 🇨🇳 Hansoh touts Phase 3 success for GSK-partnered ADC: The program, called risvutatug rezetecan or Ris-Rez, met its primary e…Endpoints · 17d ago↗ source
- STAT+: Roche ends Huntington’s gene-silencing programsARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The ReadoutSTAT · 17d ago↗ source
- STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and moreGerman lawmakers passed a bill that would more than double the discount on branded medicines drugmakers must provide the governmentSTAT